SCHEMBL5484260

SCHEMBL5484260

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(CN3CCN(C(=O)c4ccc(CN5CCN(C)CC5)cc4)CC3)cc2C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.54
CDK8 P49336 2/20 0.53
PTK2B Q14289 2/20 0.51
MAPK13 O15264 4/20 0.49
MAPK12 P53778 4/20 0.49
MAPK11 Q15759 4/20 0.49
ABL1 P00519 2/20 0.48
RAF1 P04049 2/20 0.48
LYN P07948 2/20 0.48
SRC P12931 2/20 0.48
MAPK9 P45984 2/20 0.48
TNF P01375 3/20 0.48
DDR2 Q16832 2/20 0.48
CIT O14578 1/20 0.48
MUSK O15146 1/20 0.48
MAP3K7 O43318 1/20 0.48
RIPK2 O43353 1/20 0.48
STK10 O94804 1/20 0.48
MAP4K4 O95819 1/20 0.48
CHEK2 O96017 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5477793 0.94 MAPK14 (0.54) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5481643 0.93 MAPK14 (0.54) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5475406 0.92 MAPK14 (0.56) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5479894 0.92 MAPK14 (0.53) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5474602 0.91 MAPK14 (0.56) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5474616 0.91 PTK2B (0.49) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5474916 0.90 MAPK14 (0.57) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5474930 0.89 PTK2B (0.48) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5482197 0.89 MAPK14 (0.52) MAPK14CDK8PTK2BMAPK13MAPK12
SCHEMBL5474936 0.89 PTK2B (0.48) MAPK14CDK8PTK2BMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-11 US claimed
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010529-A1 Nitrogenous heterocyclic compounds and medical use thereof MAPK1, NOS1, NOS2 MAPK14 12/4885CDK8 721/4885PTK2B 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.